The main findings of the study include (1) multivariate-adjusted logistic analysis demonstrated that the odds of having a risk of lung fibrosis at discharge were decreased with higher baseline levels of IFN-γ and MCP-3, measured in the early stage of the disease; (2) per 1-SD increase at baseline, the fibrotic volume decreased by 0.070% (95% CI, 0.001–0.139) for IFN-γ; and (3) the basal levels of IFN-γ and MCP-3 were comparable with the CRP in the discrimination of the occurrence of lung fibrosis in COVID-19 patients, whereas IL-6 were not. Here, IFNG is linked to COVID-19.